• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

AAO 2023: First-in-human clinical feasibility study of a dual-optic accommodating IOL system

News
Article

Daniel H. Chang, MD, shared highlights of his presentation on a first-in-human clinical feasibility study of a dual-optic accommodating IOL system.

Daniel H. Chang, MD, shared highlights of his presentation on a first-in-human clinical feasibility study of a dual-optic accommodating IOL system.

Video Transcript

Editor's note - This transcript has been edited for clarity.

Daniel H. Chang, MD: Hi, I'm Daniel Chang from Bakersfield, California. I'm here at AAO presenting a paper entitled, First-in-human feasibility study of a dual-optic accommodating IOL system. This is basically a study looking at the first-in-human results with the OmniVu accommodating lens [Atia Vision]. So this is a lens that's a two-part lens. Now there's a number of accommodating systems out there. This one has a base which actually accommodates, so it's a silicone base with silicone oil that goes into the capsular bag so that with accommodation, there's a change in power.

There's a secondary optic, which is a hydrophobic, acrylic design that basically adjusts or sets the power of the lens. So the dual-optic system, I personally had some experience implanting this in Panama. But this study actually presents the 12-month data of the implants that were done in India and Georgia—the Republic of Georgia, not the state of Georgia. It was basically 16 patients (21 eyes), and we looked at basically uncorrected and best-corrected visual acuity monocularly and binocularly. And basically for a binocular uncorrected visual acuity—which is basically what patients live with—distance vision was around 20/16; the intermediate vision about 20/20; and the near vision was about 20/25, not quite 20/25. With the monocular distance corrected or best-corrected—that's the functionality of the lens—it was about 20/16 distance, a little off of 20/28 Intermediate; and about 20/32 at near. So excellent visual acuity performance.

From a refraction standpoint, 94% of eyes within half a diopter at 12 months, so very good refractive and visual stability over time. And additionally from a contrast sensitivity standpoint, very favorable compared to common monofocal intraocular lenses.

Additionally, we looked at the defocus curve, which showed about three diopters of defocus at the 20/32 level or better monocularly at 4.2 diopters binocularly. Safety performance was good as well. When I implanted the lens, it was a fairly routine surgery. It's a little bit different instrumentations—maybe need to improve is a 3.5 millimeter incision, which is quite acceptable given the size of the lens. Hopefully, you can actually review the video and see how this looks. But it's a very promising approach to accommodating intraocular lenses. So in summary, early human data...very promising visual results...functionality and performance and looking forward to get more data on this.

Related Videos
Video 2 - 1 KOL is featured in, "Advances in Technology for SMILE procedure"
Video 1 - 1 KOL is featured in, "Overview of Small Incision Lenticule Extraction (SMILE)"
Vicki Chan, MD, shares pearls for leveraging the power of social media in health care
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
© 2024 MJH Life Sciences

All rights reserved.